On June 15, 2022 Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing multiple first-in-class and best-in-class approaches that enhance regulatory T cells (Tregs) function in vivo, including autologous and allogeneic Treg-derived exosome therapeutics, and novel biologics, reported the execution of an option agreement for exclusive worldwide rights to a novel and proprietary technology platform enabling exosome engineering from Carnegie Mellon University (Press release, Coya Therapeutics, JUN 15, 2022, View Source [SID1234635089]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The exclusive option agreement involves the intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids (EPHs), a tether-based exosome functionalization strategy that enables Treg exosomes to be homed to proteins of interest, while delivering select payloads into those targeted cells.
"This collaboration with Carnegie Mellon University further solidifies Coya’s thought leadership in the global exosome therapeutics field, beyond Treg-derived exosomes alone," stated Howard Berman, Ph.D., CEO of Coya Therapeutics. "Nanoengineering exosomes with such manufacturing efficiency to produce EPHs that can be customized to any surface protein, delivering growth factors or drugs, while enhancing cellular uptake and bioactivity is the future of targeted therapies."
Previously, most techniques to modify exosomes relied on complex molecular biology tools or degradation of exosomes innate functionality. EPHs overcome many of these limitations by creating a method that rapidly and efficiently modifies exosomes with a DNA-cholesterol tether. The technology leverages single stranded synthetic DNA with attached cholesterol, binding a complementary strand of DNA linked to a bioactive agent. As a result, a number of different types of cargos can be readily attached to the exosome surface while also tethering immune modulating cargoes inside the exosome.
"The next step of our development program will be to leverage EPHs to validate functional activity of our Treg-derived exosomes that home in and bind to high profile protein targets that drive specific disease processes. Additionally, these EPHs will be loaded with identified payloads to enhance efficacy," stated Adrian Hepner, M.D., Ph.D., Chief Medical Officer of Coya Therapeutics.
Drs. Subha Das and Phil Campbell of Carnegie Mellon University added: "Targeted Treg exosome therapeutics that are directed to epitopes and proteins of interest, while delivering potent growth factors, drugs or other cargo, represent an innovative platform that is advantageous on many fronts relative to other CAR Treg directed platforms. We are excited and committed in joining this collaboration with Coya Therapeutics."